1 - 10 of about 1176 releases
Martinsried/Munich, December 22, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) has closed an equity funding agreement with Yorkville Group’s YA Global Investments L.P. of Jersey City, NJ, USA (YA Global). Under the terms of the agreement, MediGene has the option to take up YA Global’s... (...)
o Trial will evaluate Efficacy and Safety of ralfinamide versus placebo in approximately 400 patients o 12 weeks treatment with double blind 40 week extension o First of two potentially pivotal studies in NLBP Milan, Italy – December 22, 2008 - Newron Pharmaceuticals S.p.A. (“Newron”), a research... (...)
Geneva, Switzerland, 17 December 2008 - Addex Pharmaceuticals (SWX:ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 as a migraine prevention therapy in people who suffer from 3 or more migraine attacks per month. ADX10059 is a first-in-class migraine... (...)
- Terms include over $200 million in fees, milestones and royalties - CAMBRIDGE, Mass. – December 11, 2008 – Ascent Therapeutics, Inc., a biopharmaceutical company developing Pepducin lipopeptides, a novel class of G-protein coupled receptor (GPCR) modulators, today announced that it has entered... (...)
Halle/Saale, December 10, 2008 -- Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the United States Patent Office issued to Probiodrug the US patent no. 7,462,599 covering compounds and... (...)
Primacyt Cell Culture Technology GmbH und Riemser Arzneimittel AG erhalten Auszeichnung zum Thema: „Förderung methodischer Arbeiten mit dem Ziel der Einschränkung und des Ersatzes von Tierversuchen“. Die Schweriner Primacyt Cell Culture Technology GmbH und die Riemser Arzneimittel AG aus... (...)
9 December 2008 - Ark Therapeutics Group plc ("Ark" or the "Company") announces today that the Finnish National Agency for Medicines (NAM) has renewed Ark's licence to produce gene-based medicine for commercial supply in Europe. The renewed Good Manufacturing Practice (GMP) certification has been... (...)
Evaluating RGB-286638 Multi-Targeted Protein Kinase Inhibitor in Patients with Advanced Solid Tumors Martinsried/Munich (Germany), and Princeton, N.J., December 9, 2008 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that enrollment has opened in a Phase 1 study... (...)
LENEXA, Kansas – December 8, 2008 – CyDex Pharmaceuticals, Inc. today announced that it has received orphan-drug designation from the U.S. Food and Drug Administration (FDA) for melphalan “as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation.”... (...)
Milan, Italy – December 3, 2008 - Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, today announced that it has entered into an equity funding agreement with YA Global Investments, L.P. (”YA Global”), to support the continued... (...)
Next results →